Abstract: This study aimed to encapsulate Celastrus paniculatus seed oil (CPSO) in 2-hydroxypropyl-β-cyclodextrin (HPβCD) cavities and investigate their biological activity, physicochemical stability, and skin penetration by vertical Franz diffusion cells of the CPSO-HPβCD inclusion complex formulations. For biological activity studies-including 2,2-diphenyl-1-picryhydrazyl radical (DPPH) scavenging, metal ion chelating, and inhibition of lipid and tyrosinase inhibition activities-the CPSO-HPβCD inclusion complex exhibited lower inhibition activity than free CPSO. CPSO-HPβCD dispersion, serum, and gel formulations were prepared. All formulations containing the CPSO-HPβCD inclusion complex showed no significant changes in physical characteristics after three months' storage. The percentages of oleic acid remaining in all formulations were over 80% of the initial amount during a three-month stability study. For the skin-penetration study, compared to other formulations, the CPSO-HPβCD serum formulation exhibited the highest cumulative amount of oleic acid in the whole skin and flux through receptor fluid, after six hours, of 32.75 ± 1.25 µg/cm 2 and 1.02 ± 0.15 µg/cm 2 /h, respectively. The CPSO-HPβCD serum formulation also showed the proper viscosity. Hence, the CPSO-HPβCD inclusion complex will be beneficial for the further development of cosmeceutical products.
Introduction
Celastrus paniculatus is a member of the Celastraceae family, which is a large woody climber (called a climbing shrub) with a yellow corky bark [1] . It is a native of the Indian continent but is known to grow wildly in Indonesia, Laos, Malaysia, Myanmar, and Thailand, as well as numerous Pacific islands [2] . The plants exhibit varying degrees of therapeutic values, some of which include its use in the treatment of cognitive dysfunction, epilepsy, insomnia, rheumatism, gout, and dyspepsia [3] . The oil from its seeds, which are the most commonly used plant part, is rich in oleic acid (54.42%), which is the main fatty acid in the oil, together with palmitic acid (20.0%), linoleic acid (15.51%), and stearic
Preparation of the C. paniculatus Seed Oil
The C. paniculatus seeds were gathered from the Samoeng district, Chiang Mai, Thailand, from January to June 2013. Voucher specimens No. HRDI 58 C0023-22 were deposited at Highland Research and Development Institute, Thailand. The dried seeds were cold-pressed using a Thai traditional cold-press machine. The yellowish-orange oil was obtained with a percentage yield of 26.09% w/w.
Determination of Oleic Acid Contents by HPLC
Oleic acid was selected since it contains the highest CPSO fatty acid profile. The oleic acid content in CPSO was determined by high performance liquid chromatography (HPLC) (Luna ® C18 10 m 250 mm × 4.60 mm Column (Phenomenex, Torrance, CA, USA), LC1200UV/VIS detector and LC1100HPLC pump) using the mobile phase of 95% (v/v) acetonitrile mixed with 5% (v/v) of 0.1% (v/v) glacial acetic acid, an injection volume at 20 µL, a flow rate of 1 mL/min, and the ultraviolet (UV) detector at 205 nm [7] . The oleic acid content was determined from the HPLC chromatogram in comparing the standard oleic acid with the oleic standard curve equation: y = 4 × 10 −5 x − 0.1649, R 2 = 0.99996.
Encapsulation of C. paniculatus Seed Oil in HPβCD
The co-evaporation method was used, with some modifications [14] . Briefly, HPβCD was dissolved with ethanol (95%) and mixed with CPSO at the weight ratio (CPSO:HPβCD) of 1:1, 1:2, 1:3, 1:4, and 1:5. Ethanol was eliminated by a rotary evaporator. The percentage yields of each formulation were calculated on a dry-weight basis.
Physicochemical Characteristics of Encapsulated HPβCD

Determination of Maximum Encapsulation
The concentrations of encapsulation were increased from 16.67 to 50% w/w at the weight ratio (CPSO:HPβCD) of 1:5, 1:4, 1:3, 1:2, and 1:1, respectively. The highest CPSO encapsulation was the target to involve the highest bioactive compounds in the inclusion complex. The maximum encapsulation was indicated from the maximum concentration, which produced no oil leakage on paper for 12 hours at 25 ± 2 • C. The inclusion ratio was calculated using Equation (1) , whereas the total recovery was calculated using Equation (2) [15] .
Inclusion ratio (%) = CPSO content of inclusion complex Initial addition of CPSO × 100
Total recovery (%) = Recovery weight of inclusion complex Initial weight of CPSO + HPβCD powder × 100
The CPSO content in Equation (1) was calculated from the HPLC analysis of biomarker oleic acid in CPSO, which could calculate the amount of CPSO in the inclusion complex.
Morphology and Particle Size of Inclusion Complex
The morphology of the HPβCD powder and the inclusion complex in the solid state were determined using a scanning electron microscope (SEM; JSM5410-LV, JEOL, Tokyo, Japan) at 200× and 100× magnification, with JEOL SemAfore software (Tokyo, Japan). The diameters of the empty and CPSO-loaded inclusion complexes in the form of solutions were determined using dynamic light scattering (DLS), Zetasizer 300HSA (Malvern Instruments, Malvern, UK), based on photon correlation spectroscopy. The analysis (n = 5) was carried out for 100 s at room temperature (27 ± 2 • C). All samples were diluted 30 times with freshly filtrated Millipore water (Millipore Corp., Bedfore, MA, USA) for particle measurement.
Biological Studies of the CPSO-HPβCD Inclusion Complex
The biological activities of the five serial concentrations of inclusion complex were investigated by comparing with non-encapsulated CPSO and standard reagents using the following methods: DPPH radical scavenging assay [16] , lipid peroxidation inhibition activity [17] , metal ion chelating [18] , and tyrosinase inhibition assay [19] . Further, the sample concentrations providing 50% of each activity (IC 50 ) were calculated.
Preparation of Formulations
The dispersion of the inclusion complex (CPSO-HPβCD dispersion) was prepared by incorporating 3% w/w of the CPSO-HPβCD inclusion complex into propylene glycol. Briefly, 1% w/w of Carbopol ® 941 (Lubrizol, Wickliffe, OH, USA) was dispersed in water with gentle stirring to prepare the stock solution of Carbopol gel. The serum base was prepared using 65% w/w of propylene glycol and 35% w/w of the stock solution of Carbopol ® gel. The CPSO-HPβCD inclusion complex (3% w/w) was incorporated into the serum base (CPSO-HPβCD serum) and gel (CPSO-HPβCD gel) base.
Stability of CPSO and CPSO-HPβCD Inclusion Complex Formulations
All inclusion-complex formulations, CPSO, and oleic acid dispersions in propylene glycol were kept in glass vials with aluminum caps and stored at 4 ± 2, 25 ± 2, and 45 ± 2 • C (65 ± 5% relative humidity) for three months. At the baseline and one, two, and three months, the samples were withdrawn and assayed for physical (separation layer, color change, and pH) and chemical stability by HPLC using oleic acid as a marker.
In Vitro Skin Permeation Study
Skin Sample
The abdominal skin of male rats (Sprague-Dawley strain, 150-200 g) was shaved with an electric clipper. The rats were sacrificed, and the abdominal skin was excised. The excess subcutaneous fat was carefully removed. The protocol was approved by the ethical committee of the Faculty of Medicine, Chiang Mai University in Thailand (protocol number: 20/2553).
CPSO Sample Preparation
All formulations (CPSO-HPβCD dispersion, serum, and gel) contained 3% w/w of the inclusion complex with a CPSO:HPβCD ratio of 1:3. Thus, the final concentration of CPSO was 0.75% w/w. Free CPSO in propylene glycol (CPSO oily solution) at 0.75% w/w was used as a control of the permeation study.
Skin-Permeation Study
Skin-permeation studies of oleic acid from various formulations were introduced using vertical Franz diffusion cells [20] having an area between the donor and the receiver chamber of 2.46 cm 2 and a volume of the receptor fluid of 13 mL. The receptor fluid contained phosphate-buffered saline (PBS, pH 7.4), which was constantly stirred at 100 rpm with a small magnetic bar and temperature was controlled at 32 ± 2 • C throughout the experiment. The skin was mounted with the stratum corneum side facing upward to the donor compartment, and the subcutaneous side was in contact with the medium. The sample (1 µL) was placed directly onto the skin and covered the donor compartment with paraffin film (n = 6). The cells were stopped at one, two, four, and six hours. Samples in the receptor fluid were analyzed by HPLC as described before. The skin was cut into small pieces; the oleic acid in the skin was extracted by absolute ethanol under sonication for 10 minutes in an ice bath and filtered. The filtrate was assayed for oleic content by HPLC. Cumulative amounts of oleic acid in the whole skin (WS) and receptor fluid (RF) were calculated.
Statistical Analysis
The results are expressed as mean ± standard deviation (SD). A Kruskal-Wallis test was used to evaluate the significance of differences at a p-value > 0.05.
Results and Discussion
Physical Characteristics of C. paniculatus Seed Oil (CPSO)
CPSO has a woody, earthy smell, and is yellowish orange in appearance. The HPLC analysis showed that the CPSO in this study was mainly composed of cis-9-oleic acid (43.85% w/w). Other compounds were also found in the oil, such as palmitic acid (24.12%), stearic acid (3.01%), and myristic acid (0.48%). The active constituents of CPSO have also been reported in several studies, and it is composed of several fatty acids [21] [22] [23] .
Physical Characteristics of the CPSO-HPβCD Inclusion Complex
The inclusion ratio and total recovery of the CPSO-HPβCD inclusion complex at various weight ratios are shown in Table 1 . When the encapsulated concentration of CPSO was more than 25% w/w of CPSO, oil spots on the surface of the paper were observed after standing for 12 hours. The suitable encapsulation of CPSO in HPβCD cavities occurred at the weight ratio (CPSO: HPβCD) of 1:3 or 25% w/w of CPSO. The total recovery was 87.5 ± 3.4%. Driving forces between HPβCD and the bioactive compounds in CPSO, such as fatty acids, have been proposed to explain the complex formation energy, including hydrogen bonds, van der Waals forces, hydrophobic interactions, and the release of high-energy water molecules from the cavity [24] . A previous study reported that hydrogen bonds and hydrophobic interactions were detected between a thyme essential oil constituent and β-cyclodextrin using IR and proton nuclear magnetic resonance ( 1 H-NMR) spectroscopy [25, 26] . Moreover, the main driving force of complex formation is the release of enthalpy-rich water molecules from the hydrophobic cavity of HPβCD [27] . In the encapsulation process, water molecules are displaced by more lipophilic guest molecules present in the solution, resulting in a nonpolar-nonpolar association and a decrease of the cyclodextrin ring strain; this results in a more stable, lower-energy state [28] . Representative SEM images of HPβCD powder, blank HPβCD, which processed the inclusion procedure and CPSO-HPβCD inclusion complex, are illustrated in Figure 1 . The HPβCD powder before the inclusion procedure had a round porous shape with an average size of about 70 ± 24 µm. The blank HPβCD had a matte surface, whereas the CPSO-HPβCD inclusion complex in solid state showed irregular-shaped crystals with a glossy smooth surface without CPSO excess on their surface at a size of about 554 ± 78 µm. The CPSO-HPβCD inclusion complex appeared as the mean particle sizes in the solution form of HPβCD powder, blank HPβCD, and the CPSO-HPβCD inclusion-complex solutions measured by DLS were 103. 30 cyclodextrin using IR and proton nuclear magnetic resonance ( 1 H-NMR) spectroscopy [25, 26] . Moreover, the main driving force of complex formation is the release of enthalpy-rich water molecules from the hydrophobic cavity of HPβCD [27] . In the encapsulation process, water molecules are displaced by more lipophilic guest molecules present in the solution, resulting in a nonpolarnonpolar association and a decrease of the cyclodextrin ring strain; this results in a more stable, lowerenergy state [28] .
Representative SEM images of HPβCD powder, blank HPβCD, which processed the inclusion procedure and CPSO-HPβCD inclusion complex, are illustrated in Figure 1 . The HPβCD powder before the inclusion procedure had a round porous shape with an average size of about 70 ± 24 µ m. The blank HPβCD had a matte surface, whereas the CPSO-HPβCD inclusion complex in solid state showed irregular-shaped crystals with a glossy smooth surface without CPSO excess on their surface at a size of about 554 ± 78 µ m. The CPSO-HPβCD inclusion complex appeared as the mean particle sizes in the solution form of HPβCD powder, blank HPβCD, and the CPSO-HPβCD inclusioncomplex solutions measured by DLS were 103.30 ± 11.74, 112.71 ± 6.97, and 240.95 ± 13.38 nm with the pdI of 0.32, 0.28, and 0.39, respectively. (Table 2 ). This may be due to the shielding effect of HPβCD, and when hydrophobic bioactive compounds such as CPSO were encapsulated in the bucket-shaped cavity, which may have led to the sustained release action of the active compound [29] . Other researchers have reported that CPSO can be used as a potential source for new drug development in treating various disorders caused by extreme oxidative stress, given its strong antioxidant properties [30] . Tyrosinase inhibition activity has been used to evaluate the skin-whitening effect, and kojic acid, arbutin, and ascorbic acid have been used as well-known standard whitening agents. Since our previous [7] and present study report that CPSO and CPSO-HPβCD exhibit high tyrosinase inhibition activity, the biological effect expected from this cosmetic formulation was the whitening effect, and the CPSO-HPβCD inclusion complex may have potential to develop cosmeceutical products. Moreover, one mechanism of the tyrosinase inhibitor is to chelate to the tyrosinase enzyme pocket at the copper ion. The metal ion chelation test is the preliminary test for chelation with the protein of the enzyme in the pocket [31] . If the extract shows high metal ion chelation and tyrosinase inhibition activities, it may have high whitening effects via the enzyme chelation mechanism. 
Physical Characteristics of CPSO-HPβCD Inclusion-Complex Formulations
All formulations containing the CPSO-HPβCD inclusion complex-including dispersion (CPSO-HPβCD dispersion), serum (CPSO-HPβCD serum), gel (CPSO-HPβCD gel), and CPSO oily solution formulations-had a yellow appearance. The CPSO oily solution formulation had a separation layer of CPSO on the surface after standing for three hours. The yellow separation layer might have occurred because the CPSO concentration was more than the maximum capacity of oil dispersion in propylene glycol. Moreover, after three months of storage, the color of the CPSO oily solution had changed from yellow to pale yellow, especially when kept at 45 • C. This might be due to the thermal instability of pigment compounds in CPSO. All other CPSO-HPβCD formulations had no significant color change with the CIELAB color analysis (data not shown) with a pH of approximately 6.5.
Chemical Characteristics of Oleic Acid in CPSO-HPβCD Inclusion Complex and CPSO-HPβCD Formulations
The chemical stability, presented as the percent remaining of oleic acid of various formulations at 4, 25, and 45 • C for three months, is shown in Figure 2 . The non-inclusion complex of the oleic solution showed the lowest remaining content (64.03 ± 1.45%) of oleic acid after three months at every storage temperature. As such, the double bonds in the chemical structures of fatty acids can be oxidized and cause the rapid onset of oil rancidity when exposed to the environment [32] . This result is in agreement with a previous study, which found that the HPβCD inclusion complex can protect the inclusion substance against the environment [33] . The CPSO-HPβCD inclusion complex at 45 • C had the lowest remaining oleic acid content (88.47 ± 4.14%), whereas those at 4 • C and 25 • C had remaining oleic acid contents of 94.97 ± 1.71 and 90.54 ± 3.41%, respectively. However, no significant difference existed in the remaining content of oleic acid of the CPSO-HPβCD inclusion complex among the three storage temperatures.
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The chemical stability, presented as the percent remaining of oleic acid of various formulations at 4, 25, and 45 °C for three months, is shown in Figure 2 . The non-inclusion complex of the oleic solution showed the lowest remaining content (64.03 ± 1.45%) of oleic acid after three months at every storage temperature. As such, the double bonds in the chemical structures of fatty acids can be oxidized and cause the rapid onset of oil rancidity when exposed to the environment [32] . This result is in agreement with a previous study, which found that the HPβCD inclusion complex can protect the inclusion substance against the environment [33] . The CPSO-HPβCD inclusion complex at 45 °C had the lowest remaining oleic acid content (88.47 ± 4.14%), whereas those at 4 °C and 25 °C had remaining oleic acid contents of 94.97 ± 1.71 and 90.54 ± 3.41%, respectively. However, no significant difference existed in the remaining content of oleic acid of the CPSO-HPβCD inclusion complex among the three storage temperatures. The chemical stability of each formulation-including CPSO-HPβCD dispersion, CPSO-HPβCD serum, CPSO-HPβCD gel, and CPSO oily solution-was also determined as the amount of oleic acid remaining under the three storage temperatures (Figure 2 ). The CPSO oily solution had the lowest percentages of oleic acid remaining after three months at 4, 25, and 45 • C of 72.68 ± 1.78, 68.26 ± 2.41, and 60.85 ± 3.41%, respectively. The remaining percentages' significant decrease (p > 0.05) might be because the oleic acid in the CPSO oily solution formulation was not protected by the HPβCD structure, leading to a higher oxidation rate by the surrounding environment. This effect might convert oleic acid to ketone or aldehyde, resulting in rancidity. Furthermore, a separation layer of CPSO was found on top of the CPSO oily solution. However, the formulations that contained the CPSO-HPβCD inclusion complex (CPSO-HPβCD dispersion, serum, and gel) had remaining percentages of oleic acid over 80% when compared to the initial formulation under all storage temperatures for three months. The CPSO-HPβCD dispersion formulation exhibited the highest remaining content of oleic acid after three months at 4, 25, and 45 • C of 93.56 ± 1.87, 92.71 ± 2.34, and 88.00 ± 2.01% of the initial amount, respectively.
Skin Permeation of CPSO-HPβCD Inclusion-Complex Formulations
The rat-skin model may not be the best choice for a skin-permeation study. However, rodent skin (mice, rats, and guinea pigs) is the most commonly used skin in in vitro percutaneous permeation studies because of its availability. The advantages of these animals are their small size, uncomplicated handling, and relatively low cost [34] . Among rodents, rat skin has more structural similarities to human tissue. Except for rat skin, rodent skin generally shows higher permeation rates than human skin [35, 36] . Nevertheless, rat skin was used in the skin-permeation assessment [37] [38] [39] [40] . Moreover, the permeation kinetic parameters are frequently comparable with human skin. The cumulative amount of oleic acid used as a chemical marker of CPSO in various formulations in the whole skin and the receptor fluid within six hours is shown in Figure 3 . The cumulative amount of oleic acid in all formulations gradually increased in both the whole skin and the receptor fluid throughout the experiment. The HPβCD inclusion complex containing CPSO in serum formulation (CPSO-HPβCD serum) exhibited the highest cumulative amount of oleic acid in the whole skin after six hours of 32.75 ± 1.25 µg/cm 2 , followed by the CPSO-HPβCD dispersion (29.28 ± 2.12 µg/cm 2 ), and CPSO-HPβCD gel (25.25 ± 2.15 µg/cm 2 ). The fluxes that permeated through the rat skin into the receptor fluid at six hours for the various formulations were calculated using the linear part of the correlation between the cumulative amount of oleic acid divided by the unit area (2.46 cm 2 ) and time (six hours). The CPSO-HPβCD serum exhibited the highest oleic acid flux after six hours, which was 1.02 ± 0.15 µg/cm 2 /h, followed by the CPSO-HPβCD gel (0.80 ± 0.12 µg/cm 2 /h), and CPSO-HPβCD dispersion (0.75 ± 0.01 µg/cm 2 /h). The CPSO oily solution formulation exhibited the lowest cumulative amount in the whole skin and flux through the receptor fluid after six hours of 15.61 ± 2.11 µg/cm 2 and 0.13 ± 0.01 µg/cm 2 /h, respectively. All CPSO-HPβCD formulations significantly appeared to penetrate the skin more efficiently, whereas the CPSO oily solution exhibited lower penetration with some remaining oil on the skin surface. In addition, superior skin penetration of the inclusion complex was observed in the serum and dispersion formulations (CPSO-HPβCD serum-dispersion, p > 0.05) compared to the CPSO-HPβCD inclusion complex in gel formulation (CPSO-HPβCD gel). This might be due to the viscosity of the formulations and the steric effect of the gel structure, which may retard the skin penetration of oleic acid in CPSO [41] . Moreover, the penetration enhancer effect of propylene glycol [42] -which was used in the CPSO oily solution, CPSO-HPβCD dispersion, and CPSO-HPβCD serum via pure cosolvent effect [43] or solvating the α-keratin structures of the cells [44] -showed lower influence than the HPβCD inclusion complex in skin penetration.
CPSO oily solution. This might be due to the effect of HPβCD on CPSO solubility. The aqueous solubility ability was also found in other substance studies (i.e., griseofulvin and phenothiazine cyclodextrin complexation) [48, 49] . Finally, this study suggests that the inclusion complex in serum formulation may be the most suitable system for topical application, given that it had the highest skin penetration of oleic acid, proper viscosity, and could be removed after skin application. However, the systemic toxicity of this formulation should be a concern. 
Conclusions
CPSO, which is primarily composed of oleic acid, was incorporated in HPβCD cavities to improve its stability and skin penetration. The inclusion ratio and total recovery of the CPSO-HPβCD inclusion complex were 92.4 ± 0.7% and 87.5 ± 3.4%, respectively. The CPSO-HPβCD inclusion complex in a solid state showed irregular-shaped crystals with a glossy smooth surface. The mean particle sizes of the HPβCD powder, blank HPβCD, and CPSO-HPβCD inclusion-complex solutions measured by DLS were 103.30 ± 11.74, 112.71 ± 6.97, and 240.95 ± 13.38 nm, respectively. For biological activity studies-including DPPH scavenging, metal ion chelating, inhibition of lipid, and tyrosinase inhibition activities-the CPSO-HPβCD inclusion complex exhibited lower inhibition activity than free CPSO. This inclusion complex was prepared as CPSO-HPβCD dispersion, serum, and gel formulations. All CPSO-HPβCD formulations showed no significant change in color, with a pH of approximately 6.5, and the oleic acid percentages remaining in all formulations were over 80% of the initial amount when stored at 4, 25, and 45 °C for three months. For the rat skin penetration study using Franz diffusion cells, the observant oleic acid was found in the receptor fluid, especially in CPSO-HPβCD formulations. The CPSO-HPβCD serum formulation exhibited the highest cumulative amount of oleic acid in the whole skin and flux through receptor fluid after six hours of 32.75 ± 1.25 µ g/cm 2 and 1.02 ± 0.15 µ g/cm 2 /h, respectively. The CPSO oily solution formulation exhibited the lowest cumulative amount in the whole skin and flux through the receptor fluid after six hours of 15.61 ± 2.11 µ g/cm 2 and 0.13 ± 0.01 µ g/cm 2 /h, respectively. This result can be applied to further However, oleic acid was found in the receptor fluid in all formulations, which means that CPSO in all formulations, especially in CPSO-HPβCD formulations, could penetrate the blood system, which may be due to its small particle size. In the pharmaceutical field, the formulations of an increasing amount of marketed drugs include cyclodextrins because of their capacity to trap drugs into their cavity, enabling their use in drug delivery to facilitate the body-tissue penetration of hydrophilic or hydrophobic drugs [45, 46] . Even if cyclodextrins could be harmful to the human organism only at extremely high concentrations [47] , the toxicity of CPSO should be evaluated to further develop the CPSO-HPβCD product. In this study, the abilities of the CPSO oily solution and CPSO-HPβCD formulations to be removed after skin application were compared. The results showed that the CPSO-HPβCD formulation was easier to remove by water after skin application than the CPSO oily solution. This might be due to the effect of HPβCD on CPSO solubility. The aqueous solubility ability was also found in other substance studies (i.e., griseofulvin and phenothiazine cyclodextrin complexation) [48, 49] . Finally, this study suggests that the inclusion complex in serum formulation may be the most suitable system for topical application, given that it had the highest skin penetration of oleic acid, proper viscosity, and could be removed after skin application. However, the systemic toxicity of this formulation should be a concern.
CPSO, which is primarily composed of oleic acid, was incorporated in HPβCD cavities to improve its stability and skin penetration. The inclusion ratio and total recovery of the CPSO-HPβCD inclusion complex were 92.4 ± 0.7% and 87.5 ± 3.4%, respectively. The CPSO-HPβCD inclusion complex in a solid state showed irregular-shaped crystals with a glossy smooth surface. The mean particle sizes of the HPβCD powder, blank HPβCD, and CPSO-HPβCD inclusion-complex solutions measured by DLS were 103.30 ± 11.74, 112.71 ± 6.97, and 240.95 ± 13.38 nm, respectively. For biological activity studies-including DPPH scavenging, metal ion chelating, inhibition of lipid, and tyrosinase inhibition activities-the CPSO-HPβCD inclusion complex exhibited lower inhibition activity than free CPSO. This inclusion complex was prepared as CPSO-HPβCD dispersion, serum, and gel formulations. All CPSO-HPβCD formulations showed no significant change in color, with a pH of approximately 6.5, and the oleic acid percentages remaining in all formulations were over 80% of the initial amount when stored at 4, 25, and 45 • C for three months. For the rat skin penetration study using Franz diffusion cells, the observant oleic acid was found in the receptor fluid, especially in CPSO-HPβCD formulations. The CPSO-HPβCD serum formulation exhibited the highest cumulative amount of oleic acid in the whole skin and flux through receptor fluid after six hours of 32.75 ± 1.25 µg/cm 2 and 1.02 ± 0.15 µg/cm 2 /h, respectively. The CPSO oily solution formulation exhibited the lowest cumulative amount in the whole skin and flux through the receptor fluid after six hours of 15.61 ± 2.11 µg/cm 2 and 0.13 ± 0.01 µg/cm 2 /h, respectively. This result can be applied to further develop CPSO-HPβCD products for topical application. However, the toxicity of CPSO should be evaluated for further experiments. 
